Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: J Allergy Clin Immunol. 2015 Oct 21;137(3):889–898.e6. doi: 10.1016/j.jaci.2015.08.040

FIG 7.

FIG 7

Defective TLR9 induced B-cell activation in BTK-deficient XLA patients. A, Surface expression of B-cell activation markers on CD19+CD27− naïve B cells of a XLA-patient harboring a BTK mutation after no stimulation or in vitro stimulation with F(ab′)2 anti-IgM or TLR9 ligand CpG for two days. B, Quantification of CD86 and CD69 expression on CD19+CD27− naïve B cells of healthy controls (n=23) or XLA-patients (n=3) after in vitro stimulation with the TLR9 ligand CpG for two days. Each bar represents the mean ± SEM frequency.

C, Surface expression of the B-cell activation markers CD69 and CD86 on purified CD19+CD10+CD27− new emigrant/transitional or CD19+CD10−CD27− mature naïve B cells from a healthy control after in vitro stimulation as described above.